Free Trial
FRA:FRE

Fresenius SE & Co. KGaA (FRE) Stock Price, News & Analysis

Fresenius SE & Co. KGaA logo
€33.20 -0.28 (-0.84%)
(As of 12/20/2024 ET)

About Fresenius SE & Co. KGaA Stock (FRA:FRE)

Key Stats

Today's Range
€32.74
€33.29
50-Day Range
€32.21
€34.85
52-Week Range
€60.16
€80.00
Volume
2.14 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive FRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FRE Stock News Headlines

AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
UBS Sticks to Their Buy Rating for Fresenius SE & Co. KGaA (0OO9)
Deutsche Bank Keeps Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)
J.P. Morgan Remains a Buy on Fresenius SE & Co. KGaA (0OO9)
See More Headlines

FRE Stock Analysis - Frequently Asked Questions

Fresenius SE & Co. KGaA's stock was trading at €28.07 on January 1st, 2024. Since then, FRE stock has increased by 18.3% and is now trading at €33.20.
View the best growth stocks for 2024 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fresenius SE & Co. KGaA investors own include Illumina (ILMN), Daimler (DAI), Endologix (ELGX), APA (APA), Cambrex (CBM), Micron Technology (MU) and Bayer Aktiengesellschaft (BAYN).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Care Facilities
Sub-Industry
Medical Equipment
CIK
N/A
Fax
N/A
Employees
190,863
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (FRA:FRE) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners